| Characteristics . | n . | % . |
|---|---|---|
| Patients (n = 1311) | ||
| Median (IQR) age, years | 5.7 | (2.2–11.0) |
| Sex | ||
| Female | 534 | 41% |
| Male | 777 | 59% |
| Race | ||
| Asian-Pacific Islander | 51 | 4% |
| Black | 202 | 15% |
| Hispanic | 55 | 4% |
| Middle Eastern | 41 | 3% |
| Other or not reported | 22 | 2% |
| White | 940 | 72% |
| Transplants (n = 1419) | ||
| HSCT year | ||
| 1997–2000 | 327 | 23% |
| 2001–2005 | 466 | 33% |
| 2006–2010 | 347 | 24% |
| 2011–2015 | 279 | 20% |
| HSCT Indication | ||
| Genetic or inherited metabolic disorder | 280 | 20% |
| Hematological malignancy | 599 | 42% |
| Immunodeficiency | 152 | 11% |
| Nonmalignant hematological disorder | 162 | 11% |
| Other | 4 | <1% |
| Solid tumor | 222 | 16% |
| HSCT Donor Source | ||
| Allogeneic | 1183 | 83% |
| Bone marrow | 314 | 27% |
| Umbilical cord blood | 869 | 73% |
| Autologous | 236 | 17% |
| Conditioning Regimen | ||
| Myeloablative | 1300 | 92% |
| Nonmyeloablative | 68 | 5% |
| Reduced intensity | 51 | 4% |
| Characteristics . | n . | % . |
|---|---|---|
| Patients (n = 1311) | ||
| Median (IQR) age, years | 5.7 | (2.2–11.0) |
| Sex | ||
| Female | 534 | 41% |
| Male | 777 | 59% |
| Race | ||
| Asian-Pacific Islander | 51 | 4% |
| Black | 202 | 15% |
| Hispanic | 55 | 4% |
| Middle Eastern | 41 | 3% |
| Other or not reported | 22 | 2% |
| White | 940 | 72% |
| Transplants (n = 1419) | ||
| HSCT year | ||
| 1997–2000 | 327 | 23% |
| 2001–2005 | 466 | 33% |
| 2006–2010 | 347 | 24% |
| 2011–2015 | 279 | 20% |
| HSCT Indication | ||
| Genetic or inherited metabolic disorder | 280 | 20% |
| Hematological malignancy | 599 | 42% |
| Immunodeficiency | 152 | 11% |
| Nonmalignant hematological disorder | 162 | 11% |
| Other | 4 | <1% |
| Solid tumor | 222 | 16% |
| HSCT Donor Source | ||
| Allogeneic | 1183 | 83% |
| Bone marrow | 314 | 27% |
| Umbilical cord blood | 869 | 73% |
| Autologous | 236 | 17% |
| Conditioning Regimen | ||
| Myeloablative | 1300 | 92% |
| Nonmyeloablative | 68 | 5% |
| Reduced intensity | 51 | 4% |
Abbreviations: HSCT, hematopoietic stem cell transplantation; IQR, interquartile range.
| Characteristics . | n . | % . |
|---|---|---|
| Patients (n = 1311) | ||
| Median (IQR) age, years | 5.7 | (2.2–11.0) |
| Sex | ||
| Female | 534 | 41% |
| Male | 777 | 59% |
| Race | ||
| Asian-Pacific Islander | 51 | 4% |
| Black | 202 | 15% |
| Hispanic | 55 | 4% |
| Middle Eastern | 41 | 3% |
| Other or not reported | 22 | 2% |
| White | 940 | 72% |
| Transplants (n = 1419) | ||
| HSCT year | ||
| 1997–2000 | 327 | 23% |
| 2001–2005 | 466 | 33% |
| 2006–2010 | 347 | 24% |
| 2011–2015 | 279 | 20% |
| HSCT Indication | ||
| Genetic or inherited metabolic disorder | 280 | 20% |
| Hematological malignancy | 599 | 42% |
| Immunodeficiency | 152 | 11% |
| Nonmalignant hematological disorder | 162 | 11% |
| Other | 4 | <1% |
| Solid tumor | 222 | 16% |
| HSCT Donor Source | ||
| Allogeneic | 1183 | 83% |
| Bone marrow | 314 | 27% |
| Umbilical cord blood | 869 | 73% |
| Autologous | 236 | 17% |
| Conditioning Regimen | ||
| Myeloablative | 1300 | 92% |
| Nonmyeloablative | 68 | 5% |
| Reduced intensity | 51 | 4% |
| Characteristics . | n . | % . |
|---|---|---|
| Patients (n = 1311) | ||
| Median (IQR) age, years | 5.7 | (2.2–11.0) |
| Sex | ||
| Female | 534 | 41% |
| Male | 777 | 59% |
| Race | ||
| Asian-Pacific Islander | 51 | 4% |
| Black | 202 | 15% |
| Hispanic | 55 | 4% |
| Middle Eastern | 41 | 3% |
| Other or not reported | 22 | 2% |
| White | 940 | 72% |
| Transplants (n = 1419) | ||
| HSCT year | ||
| 1997–2000 | 327 | 23% |
| 2001–2005 | 466 | 33% |
| 2006–2010 | 347 | 24% |
| 2011–2015 | 279 | 20% |
| HSCT Indication | ||
| Genetic or inherited metabolic disorder | 280 | 20% |
| Hematological malignancy | 599 | 42% |
| Immunodeficiency | 152 | 11% |
| Nonmalignant hematological disorder | 162 | 11% |
| Other | 4 | <1% |
| Solid tumor | 222 | 16% |
| HSCT Donor Source | ||
| Allogeneic | 1183 | 83% |
| Bone marrow | 314 | 27% |
| Umbilical cord blood | 869 | 73% |
| Autologous | 236 | 17% |
| Conditioning Regimen | ||
| Myeloablative | 1300 | 92% |
| Nonmyeloablative | 68 | 5% |
| Reduced intensity | 51 | 4% |
Abbreviations: HSCT, hematopoietic stem cell transplantation; IQR, interquartile range.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
